Wealth Enhancement Advisory Services’s NovoCure NVCR Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.01M	Buy	61,767 +25,929	+72%	+$392K	﹤0.01%	2066
2026 Q1	$378K	Buy	35,838 +9,623	+37%	+$120K	﹤0.01%	2564
2025 Q4	$375K	Buy	26,215 +15,099	+136%	+$194K	﹤0.01%	2719
2025 Q3	$157K	Buy	+11,116	New	+$149K	﹤0.01%	3217
2021 Q3	–	Sell	-7,900	Closed	-$1.44M	–	326
2021 Q2	$1.44M	Buy	+7,900	New	+$1.54M	0.02%	158

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Wealth Enhancement Advisory Services's NVCR Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its NovoCure (NVCR) stake by 72% in Q2 2026, buying an estimated $392K and bringing the position to 61,767 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2066.

Wealth Enhancement Advisory Services first reported a position in NVCR in Q2 2021 and has held it in 5 quarters since. The position peaked at $1.44M in Q2 2021. 217 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Wealth Enhancement Advisory Services held 61,767 shares of NovoCure worth $1.01M as of Q2 2026.
Wealth Enhancement Advisory Services bought 25,929 NovoCure shares in Q2 2026, an estimated $392K.
NovoCure made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2066 holding.
Wealth Enhancement Advisory Services first reported a position in NovoCure in Q2 2021 and has held it in 5 quarters since.
Wealth Enhancement Advisory Services's NovoCure position peaked at $1.44M in Q2 2021.
217 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.